OncoMatch/Esophageal Cancer/PD-L1 (CD274)
Esophageal CancerPD-L1 (CD274) Clinical Trials
PD-L1 CPS ≥10 is the key biomarker threshold for first-line nivolumab plus chemotherapy (CheckMate 648) and pembrolizumab plus chemotherapy (KEYNOTE-590) approvals in esophageal carcinoma; both checkpoint-containing regimens are approved regardless of PD-L1 but with greater benefit at CPS ≥10. Nivolumab monotherapy is approved for PD-L1 TPS ≥1% in second-line esophageal squamous cell carcinoma. Trials investigate novel IO combinations, chemoradiation plus checkpoint therapy, and perioperative IO for resectable disease.
Top recruiting PD-L1 (CD274) Esophageal Cancer trials
Ranked by phase and US site count. See all 36 trials matched to your profile →
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Bristol-Myers Squibb
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Astellas Pharma Global Development, Inc.
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Daiichi Sankyo
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
RemeGen Co., Ltd.
M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Browse other molecular targets with active Esophageal Cancer trials.